11/21
11:34 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at TD Cowen.
Medium
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at TD Cowen.
11/21
10:45 am
kura
Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26% [Yahoo! Finance]
Medium
Report
Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26% [Yahoo! Finance]
11/21
09:45 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its price target lowered by analysts at Jefferies Financial Group Inc. from $32.00 to $28.00. They now have a "buy" rating on the stock.
Medium
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its price target lowered by analysts at Jefferies Financial Group Inc. from $32.00 to $28.00. They now have a "buy" rating on the stock.
11/21
09:00 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
11/21
08:05 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its price target raised by analysts at HC Wainwright from $32.00 to $37.00. They now have a "buy" rating on the stock.
High
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its price target raised by analysts at HC Wainwright from $32.00 to $37.00. They now have a "buy" rating on the stock.
11/20
05:02 pm
kura
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias [Yahoo! Finance]
High
Report
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias [Yahoo! Finance]
11/20
05:00 pm
kura
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
High
Report
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
11/20
05:00 pm
kura
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
High
Report
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
11/20
05:00 pm
kura
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
High
Report
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
11/20
05:00 pm
kura
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
High
Report
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
11/20
03:14 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Kura Oncology, Inc. (NASDAQ: KURA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/19
12:46 pm
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $32.00 price target on the stock.
Medium
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $32.00 price target on the stock.
11/13
01:08 pm
kura
Syndax's stock sinks by 25% despite AML trial meeting primary endpoint [Yahoo! Finance]
Low
Report
Syndax's stock sinks by 25% despite AML trial meeting primary endpoint [Yahoo! Finance]
11/13
08:06 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Medium
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
11/13
12:08 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Kura Oncology, Inc. (NASDAQ: KURA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/8
04:12 pm
kura
Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses [Yahoo! Finance]
Low
Report
Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses [Yahoo! Finance]
11/7
04:05 pm
kura
Kura Oncology Reports Third Quarter 2024 Financial Results
Medium
Report
Kura Oncology Reports Third Quarter 2024 Financial Results
11/6
05:22 pm
kura
Kura Oncology Q3 2024 Earnings Preview [Seeking Alpha]
Low
Report
Kura Oncology Q3 2024 Earnings Preview [Seeking Alpha]
11/6
10:18 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
11/6
08:06 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Low
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
11/5
09:19 am
kura
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting [Yahoo! Finance]
Low
Report
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting [Yahoo! Finance]
11/5
09:09 am
kura
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
Low
Report
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
11/4
06:37 pm
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $37.00 price target on the stock.
Low
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $37.00 price target on the stock.
10/31
07:30 am
kura
Kura Oncology to Report Third Quarter 2024 Financial Results
Low
Report
Kura Oncology to Report Third Quarter 2024 Financial Results
10/29
08:00 am
kura
Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors
Low
Report
Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors